NSCLC Gained Seven Approvals In May; More Are in Pipeline

When the FDA approved Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) on May 6, it was the first of seven approvals in non-small cell lung cancer (NSCLC) through May 29 (RSP 6/20, p. 8). While these will offer more options for people with certain forms of the condition, more treatments are still needed, says one industry expert, and the pipeline is full of an array of therapies.

Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. NSCLC makes up 84% of all lung cancers, while small cell lung cancer makes up about 13%.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
April 11

News Briefs: Amylyx Is Withdrawing ALS Drug Relyvrio in U.S., Canada

READ MORE
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
April 11

New FDA Approvals: FDA Approves BeiGene’s Tevimbra

READ MORE
test-tube
April 11

‘Significant Milestone’ Brings New Weapon to Advanced Melanoma Fight

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today